SCA
REGN icon

Snowden Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Snowden Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Sell
2,732
-132
-5% -$89.8K 0.04% 407
2026
Q1 		$2.21M Buy
2,864
+180
+7% +$138K 0.06% 312
2025
Q4 		$2.07M Buy
2,684
+400
+18% +$272K 0.05% 318
2025
Q3 		$1.28M Buy
2,284
+566
+33% +$320K 0.04% 446
2025
Q2 		$902K Sell
1,718
-213
-11% -$119K 0.03% 561
2025
Q1 		$1.22M Buy
1,931
+314
+19% +$216K 0.04% 438
2024
Q4 		$1.15M Buy
1,617
+108
+7% +$90.6K 0.04% 460
2024
Q3 		$1.59M Sell
1,509
-179
-11% -$199K 0.05% 380
2024
Q2 		$1.77M Sell
1,688
-153
-8% -$148K 0.05% 355
2024
Q1 		$1.77M Buy
1,841
+679
+58% +$646K 0.06% 347
2023
Q4 		$1.02M Buy
1,162
+36
+3% +$29.6K 0.04% 438
2023
Q3 		$927K Sell
1,126
-73
-6% -$57.4K 0.04% 437
2023
Q2 		$862K Buy
1,199
+73
+6% +$56.3K 0.03% 503
2023
Q1 		$925K Sell
1,126
-238
-17% -$180K 0.04% 476
2022
Q4 		$984K Sell
1,364
-94
-6% -$69.4K 0.04% 452
2022
Q3 		$1M Sell
1,458
-167
-10% -$105K 0.05% 422
2022
Q2 		$960K Sell
1,625
-309
-16% -$201K 0.04% 428
2022
Q1 		$1.35M Buy
1,934
+1,175
+155% +$743K 0.05% 352
2021
Q4 		$479K Sell
759
-1,051
-58% -$646K 0.02% 463
2021
Q3 		$1.1M Buy
1,810
+11
+0.6% +$6.83K 0.05% 352
2021
Q2 		$1M Buy
1,799
+314
+21% +$159K 0.05% 373
2021
Q1 		$703K Buy
1,485
+750
+102% +$365K 0.04% 416
2020
Q4 		$355K Buy
735
+222
+43% +$120K 0.02% 500
2020
Q3 		$287K Buy
513
+9
+2% +$5.46K 0.02% 475
2020
Q2 		$314K Sell
504
-22
-4% -$12.5K 0.03% 458
2020
Q1 		$257K Buy
+526
New +$217K 0.03% 456
2019
Q2 		– Sell
-511
Closed -$210K – 516
2019
Q1 		$210K Buy
+511
New +$210K 0.02% 479

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Snowden Capital Advisors's REGN Position: Q2 2026 in Review

Snowden Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 4.6% in Q2 2026, selling an estimated $89.8K and leaving 2,732 shares worth $1.7M. The position accounts for 0.04% of the portfolio, ranked #407.

Snowden Capital Advisors first reported a position in REGN in Q1 2019 and has held it in 27 quarters since. The position peaked at $2.21M in Q1 2026. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Snowden Capital Advisors held 2,732 shares of Regeneron Pharmaceuticals worth $1.7M as of Q2 2026.
  • Snowden Capital Advisors sold 132 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $89.8K.
  • Regeneron Pharmaceuticals made up 0.04% of Snowden Capital Advisors's portfolio in Q2 2026, its #407 holding.
  • Snowden Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 27 quarters since.
  • Snowden Capital Advisors's Regeneron Pharmaceuticals position peaked at $2.21M in Q1 2026.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.